Urgent.News

What's breaking now, across thousands of outlets.

Health & Medicine

STAT+: Biotech’s next big bet: A Tenax study of a heart failure treatment

Tenax Therapeutics will soon report results from a Phase 3 study that is one of the biggest binary biotech stock events remaining in the sector this year.

STAT+: Biotech’s next big bet: A Tenax study of a heart failure treatment

We haven't written up this one. STAT News has the full story — the link below goes straight to it.

Read the original at statnews.com →

More in Health & Medicine

More from Thursday 6 August →